Equities

CRISPR Therapeutics AG

CRISPR Therapeutics AG

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)46.29
  • Today's Change-0.97 / -2.05%
  • Shares traded356.00
  • 1 Year change-31.49%
  • Beta1.5971
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Key statistics

On Thursday, CRISPR Therapeutics AG (CRSP:NMQ) closed at 46.29, 6.61% above its 52-week low of 43.42, set on Sep 06, 2024.
52-week range
Today
43.42Sep 06 202491.10Feb 22 2024
Short selling activity
Low
Med
High
Provided by S&P Global Market Intelligence
Open47.21
High47.21
Low45.51
Bid45.50
Offer47.00
Previous close47.26
Average volume2.17m
Shares outstanding85.35m
Free float83.89m
P/E (TTM)--
Market cap3.95bn USD
EPS (TTM)-2.80
USD
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼

Events & Activity

  • CRSP:NMQ price moved over +1.23% to 47.83
  • CRSP:NMQ price rises above 50-day moving average to 47.91 at 09:31 GMT
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
S&P Global Market Intelligence Short Selling Activity © S&P Global Market Intelligence. All rights reserved.
Although S&P Global Market Intelligence has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of S&P Global Market Intelligence on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.